The 24-year course of major depression in patients with borderline personality disorder and personality-disordered comparison subjects.


Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
01 11 2019
Historique:
received: 22 02 2019
revised: 29 04 2019
accepted: 02 08 2019
pubmed: 11 8 2019
medline: 4 7 2020
entrez: 11 8 2019
Statut: ppublish

Résumé

This study had two main objectives. The first was to detail the prevalence of major depressive disorder over 24 years of follow-up for both patients with borderline personality disorder (BPD) and comparison subjects with other personality disorders (OPD). The second was to determine time-to-remission, recurrence, and new onset of major depression among these two groups of patients. The SCID-I was administered to 290 borderline inpatients and 72 personality-disordered comparison subjects during their index admission. It was also re-administered at 12 contiguous two-year follow-up periods. The prevalence of major depression was significantly higher for borderline patients over time but declined significantly over time for those in both study groups. In terms of time to events, 93% of borderline patients meeting criteria for major depression at baseline experienced a two-year remission by the time of the 24-year follow-up. Recurrences were about as common (90% for those with remitted major depression). New onsets of major depression were also very common (86% for those without major depression during their index admission). Results may not pertain to less severely ill patients with BPD and those in less treatment. Taken together, the results of this study suggest that the remitting-recurring course of major depression in borderline patients is very similar to the course of major depression in those with other types of personality disorder and those for whom major depression is their primary disorder.

Sections du résumé

BACKGROUND
This study had two main objectives. The first was to detail the prevalence of major depressive disorder over 24 years of follow-up for both patients with borderline personality disorder (BPD) and comparison subjects with other personality disorders (OPD). The second was to determine time-to-remission, recurrence, and new onset of major depression among these two groups of patients.
METHODS
The SCID-I was administered to 290 borderline inpatients and 72 personality-disordered comparison subjects during their index admission. It was also re-administered at 12 contiguous two-year follow-up periods.
RESULTS
The prevalence of major depression was significantly higher for borderline patients over time but declined significantly over time for those in both study groups. In terms of time to events, 93% of borderline patients meeting criteria for major depression at baseline experienced a two-year remission by the time of the 24-year follow-up. Recurrences were about as common (90% for those with remitted major depression). New onsets of major depression were also very common (86% for those without major depression during their index admission).
LIMITATIONS
Results may not pertain to less severely ill patients with BPD and those in less treatment.
CONCLUSIONS
Taken together, the results of this study suggest that the remitting-recurring course of major depression in borderline patients is very similar to the course of major depression in those with other types of personality disorder and those for whom major depression is their primary disorder.

Identifiants

pubmed: 31400625
pii: S0165-0327(19)30481-1
doi: 10.1016/j.jad.2019.08.005
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

109-114

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Mary C Zanarini (MC)

McLean Hospital, 115 Mill Street, Belmont, MA 02478, United States. Electronic address: zanarini@mclean.harvard.edu.

Susanne Hörz-Sagstetter (S)

McLean Hospital, 115 Mill Street, Belmont, MA 02478, United States.

Christina M Temes (CM)

McLean Hospital, 115 Mill Street, Belmont, MA 02478, United States.

Frances R Frankenburg (FR)

McLean Hospital, 115 Mill Street, Belmont, MA 02478, United States.

Katherine E Hein (KE)

McLean Hospital, 115 Mill Street, Belmont, MA 02478, United States.

D Bradford Reich (DB)

McLean Hospital, 115 Mill Street, Belmont, MA 02478, United States.

Garrett M Fitzmaurice (GM)

McLean Hospital, 115 Mill Street, Belmont, MA 02478, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH